{"id":"NCT01598090","sponsor":"Bristol-Myers Squibb","briefTitle":"Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir","officialTitle":"A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-06-14","primaryCompletion":"2015-02-04","completion":"2015-05-15","firstPosted":"2012-05-15","resultsPosted":"2019-05-21","lastUpdate":"2019-07-31"},"enrollment":881,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C Virus"],"interventions":[{"type":"BIOLOGICAL","name":"Peginterferon Lambda-1a","otherNames":[]},{"type":"BIOLOGICAL","name":"Peginterferon Alfa-2a","otherNames":["Pegasys"]},{"type":"DRUG","name":"Ribavirin","otherNames":[]},{"type":"DRUG","name":"Telaprevir","otherNames":["Incivek"]}],"arms":[{"label":"Part A: Peginterferon Lambda-1a + RBV + TVR","type":"EXPERIMENTAL"},{"label":"Part B (Arm 1): Peginterferon Lambda-1a + RBV + TVR","type":"EXPERIMENTAL"},{"label":"Part B (Arm 2): Peginterferon Lambda-2a + RBV + TVR","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine whether Peginterferon Lambda-1a (Lambda) combined with Ribavirin (RBV) and Telaprevir (TVR) is effective in the treatment of chronic Hepatitis C (CHC) compared to Peginterferon Alfa-2a (alfa-2a) combined with RBV and Telaprevir.","primaryOutcome":{"measure":"Percentage of Participants With Extended Rapid Virologic Response (eRVR) - Part A","timeFrame":"Assessed at Week 4 and Week 12, week 12 reported","effectByArm":[{"arm":"Part A: Peginterferon Lambda-1a + RBV + TVR (Open Label)","deltaMin":51.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":4},"locations":{"siteCount":104,"countries":["United States","Austria","Belgium","Brazil","Canada","Czechia","France","Germany","Israel","Italy","Poland","Russia","Spain","Switzerland","United Kingdom"]},"refs":{"pmids":["23743475"],"seeAlso":["http://www.bms.com/studyconnect/Pages/home.aspx","http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx","http://bms.com/studyconnect/Pages/home.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":27},"commonTop":["Pruritus","Nausea","Fatigue","Rash","Insomnia"]}}